Skip to content
Discover J&J
Medicines & therapies
Medical devices & technology
Discover J&J
Medicines & therapies
Medical devices & technology
Media
Contact
locationPlaceholder
Choose your country or region
Global
Global
English
North America
Canada
English
Français
United States
English
Asia Pacific
Asia Pacific (Regional)
English
Australia
English
China
中文
Hong Kong
English
中文
Japan
日本
Korea
한국어
New Zealand
English
Europe, Middle East & Africa (EMEA)
EMEA (Regional)
English
Middle East - Africa
الشرق الأوسط و أفريقيا (عربي)
Austria
Deutsch
Belgium
English
Français
Netherlands
Bulgaria
БЪЛГАРСКИ
Croatia
Hrvatski
Czech Republic
čeština
Denmark
Dansk
Estonia
English
Finland
Suomi
France
Français
Germany
Deutsch
Greece
ΕΛΛΗΝΙΚΑ
Hungary
Magyar
Ireland
English
Israel
עברית
Italy
Italiano
Latvia
English
Lithuania
English
Netherlands
Netherlands
Norway
Norsk
Poland
Polski
Portugal
Português
Romania
Română
Russia
Pусский
Serbia
Srpski
Slovakia
Slovenčina
Slovenia
Slovenščina
South Africa
English
Spain
Español
Switzerland
Français
Deutsch
Sweden
Svensk
Turkey
Türkçe
United Kingdom
English
Latin America
Latin America (Regional)
Español
Argentina
Español
Bolivia
Español
Brazil
Português
Central America and the Caribbean
Español
Chile
Español
Colombia
Español
Ecuador
Español
Mexico
Español
Paraguay
Español
Peru
Español
Uruguay
Español
Healthcare areas
Oncology
Immunology
Neuroscience
Cardiopulmonary
Products
Clinical trials
Pipeline
Patient resources
Innovative Medicine
healthcare areas
Menu
Healthcare areas
Oncology
Immunology
Neuroscience
Cardiopulmonary
Products
Clinical trials
Pipeline
Patient resources
Media
Contact
Show Search
Search Query
Submit Search
Clear
Dictate search request
Search Results
No Results
Recently Viewed
Listening...
Sorry, I don't understand. Please try again
Innovative Medicine
/
Newsroom
Newsroom
The latest news from Johnson & Johnson Innovative Medicine.
Press releases
Search Query
Submit Search
Clear
Dictate search request
Listening...
Sorry, I don't understand. Please try again
998 Results
Topic
All (998)
Cardiopulmonary (96)
Communicable diseases (143)
Company news (20)
Immunology (173)
Neuroscience (62)
Oncology (320)
Sub areas
All (998)
Autoantibody (82)
Gastroenterology (51)
Immunodermatology (35)
Maternal-fetal immunology (6)
Rare autoantibody (10)
Respiratory (3)
Rheumatic diseases (67)
Rheumatology (67)
998 results
Filters
Topic
All (998)
Cardiopulmonary (96)
Communicable diseases (143)
Company news (20)
Immunology (173)
Neuroscience (62)
Oncology (320)
Sub areas
All (998)
Autoantibody (82)
Gastroenterology (51)
Immunodermatology (35)
Maternal-fetal immunology (6)
Rare autoantibody (10)
Respiratory (3)
Rheumatic diseases (67)
Rheumatology (67)
Innovative Medicine
June 17, 2025
Johnson & Johnson seeks U.S. FDA approval of STELARA® (ustekinumab) for the treatment of pediatric Crohn’s disease
Supported by 52-week data from the Phase 3 UNITI-Jr study, submission aims to expand STELARA® indication to treat children two years of age and older
Read more
Innovative Medicine
June 15, 2025
Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease
Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA Data signal potential of novel, off-the-shelf approach in patients with extramedullary disease who face significant unmet needs
Read more
Innovative Medicine
June 13, 2025
Johnson & Johnson’s dual-targeting CAR T-cell therapy shows encouraging first results in large B-cell lymphoma
Phase 1b study suggests a promising safety profile and highlights the potential of a novel dual-targeting CD19/CD20 CAR T in patients with relapsed or refractory disease 75-80% complete response rate among evaluable patients at the recommended Phase 2 dose
Read more
Innovative Medicine
June 12, 2025
New results for Johnson & Johnson’s bleximenib demonstrate promising antileukemic activity in combination with venetoclax and azacitidine for acute myeloid leukemia
Bleximenib, an investigational selective menin inhibitor, shows potential as combination therapy for the treatment of relapsed or refractory AML and newly diagnosed, intensive chemo-ineligible AML Phase 1b data show low rate of differentiation syndrome and no cardiac safety signal of QTc prolongation
Read more
Innovative Medicine
June 12, 2025
Significant efficacy benefit of IMBRUVICA® (ibrutinib) plus venetoclax versus acalabrutinib plus venetoclax in frontline treatment of patients with chronic lymphocytic leukaemia suggested by indirect treatment comparison
Cross-study findings indicate significant clinical benefit of frontline fixed-duration ibrutinib plus venetoclax with improved likelihood of undetectable minimal residual disease and progression-free survival versus acalabrutinib plus venetoclax1 Phase 2 CAPTIVATE long-term follow-up data further supports sustained efficacy and safety profile of fixed-duration ibrutinib plus venetoclax treatment in patients receiving frontline treatment for chronic lymphocytic leukaemia2
Read more
Innovative Medicine
June 11, 2025
New data show TREMFYA® (guselkumab) is the only IL-23 inhibitor proven to significantly inhibit progression of joint structural damage in active psoriatic arthritis
TREMFYA ® demonstrated two and a half times greater ability to inhibit joint structural damage versus placebo in the Phase 3b APEX study More than 40% of TREMFYA®-treated patients across both dose groups achieved ACR50 at Week 24 Improvement in both joint and skin symptoms reinforce TREMFYA® as a first-line treatment option with a proven safety profile for adults with active psoriatic arthritis
Read more
Load More